Download App
Current Complaints | Help Center| Subscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Q-Line Biotech Ltd (QLINE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: QLINE Medical Equipment/Supplies/Accessories | Small Cap | Q-Line Biotech Share Price

BSE Share Price
Not Listed

Q-Line Biotech Ltd (QLINE)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: QLINE Medical Equipment/Supplies/Accessories | Small Cap | Q-Line Biotech Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹1,589 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹23.9
TTM Sales
₹342 Cr.
Book Value per Share
₹108.6
P/E Ratio
28.51
Industry PE
128.9
Price to Book (P/B)
6.27
Price to Sales (P/S)
4.65
EV/EBITDA
16.74
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
25.55%
Return on Capital Employed (ROCE)
22.23%
Return on Assets (ROA)
11.01%
Operating Profit Margin
30.8%
Net Profit Margin
16.31%
Gross Profit Margin
23.3%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
8.97%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
59.15%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
255.36%
Asset Quality
Promoter Holding
67.51%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹230 Cr.
Equity
₹23.3 Cr.
Face Value
₹10
All Time Low / High
₹0.00 / 0.00

Q-Line Biotech stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Not Good
Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong
Check Price chart
Q.1 Is Q-Line Biotech Ltd a good quality company?
Q-Line Biotech Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Q-Line Biotech Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Q-Line Biotech Ltd vs industry peers?
Q-Line Biotech Ltd revenue CAGR is 23.20%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Q-Line Biotech Ltd?
Promoters hold 67.51% of the Q-Line Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Q-Line Biotech Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Q-Line Biotech Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'25Mar'26TTM
ROCE % ⓘ23.3%23%-
Value Creation
Index ⓘ		0.70.6-

Growth Parameters ⓘ
Sales ⓘ313341341
Sales YoY Gr.-9%-
Adj EPS ⓘ24.738.524.4
YoY Gr.-55.7%-
BVPS (₹) ⓘ120.6152109.1
Adj Net
Profit ⓘ		38.962.757
Cash Flow from Ops. ⓘ21.821-
Debt/CF from Ops. ⓘ7.310.2-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANANA9%
Adj EPS ⓘNANANA55.7%
BVPSⓘNANANA26.1%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'25Mar'26TTM
Return on
Equity % ⓘ		20.528.718.7
Op. Profit
Mgn % ⓘ		20.431.2NAN
Net Profit
Mgn % ⓘ		12.418.416.7
Debt to
Equity ⓘ		0.80.9-
Working Cap
Days ⓘ		02780
Cash Conv.
Cycle ⓘ		01110

Valuation of Q-Line Biotech - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'23Mar'24Mar'25Mar'26
Sales183204313342
Operating Expenses ⓘ + 149166252244
Manufacturing Costs16283634
Material Costs8893146134
Employee Cost 19212735
Other Costs ⓘ 26244341
Operating Profit ⓘ 34386298
Operating Profit Margin (%) 18.5%18.7%19.7%28.7%
Other Income ⓘ + 23126
Exceptional Items ⓘ 00-17-1
Interest ⓘ 461519
Depreciation ⓘ 24711
Profit Before Tax ⓘ 30313573
Tax ⓘ 891917
Profit After Tax 21221656
PAT Margin (%) 11.7%10.6%5.0%16.3%
Adjusted EPS (₹)20.421.912.234.2
Dividend Payout Ratio (%)0%0%0%0%
PARTICULARSMar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 127162190246
Share Capital ⓘ 1.581.581.5816.28
Reserves ⓘ 126160188230
Debt +6885138186
Long Term Debt14358296
Short Term Debt54505590
Minority Interest0000
Trade Payables40595652
Others Liabilities ⓘ 15327174
Total Liabilities ⓘ 251339455558

Fixed Assets

Net Fixed Assets ⓘ +236074142
Gross Block327393172
Accumulated Depreciation9131930
CWIP ⓘ 12196319
Investments ⓘ 16291817
Inventories441059095
Trade Receivables332683126
Cash Equivalents 90304776
Others Assets ⓘ 34698183
Total Assets ⓘ 251339455558
PARTICULARSMar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 25-241716
PBT ⓘ 30313573
Adjustment ⓘ 595431
Changes in Working Capital ⓘ 3-54-63-61
Tax Paid ⓘ -12-9-8-26
Cash Flow From Investing Activity ⓘ + -26-45-77-29
Capex -26-48-80-34
Net Investments -30-00
Others ⓘ 3335
Cash Flow From Financing Activity ⓘ + 26175342
Net Proceeds from Shares ⓘ 0001
Net Proceeds from Borrowing ⓘ 6214714
Interest Paid ⓘ -4-6-15-19
Dividend Paid ⓘ 0000
Others ⓘ 2422147
Net Cash Flow ⓘ 25-52-729
PARTICULARSMar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)16.7914.978.9225.55
ROCE (%)16.7616.0716.1722.23
Asset Turnover Ratio0.730.690.790.71
PAT to CFO Conversion(x)1.19-1.091.060.29
Working Capital Days
Receivable Days6653.3063.60105.20
Inventory Days87.10133.40113.9093.50
Payable Days163.80194.10143.30146.50

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Q-Line Biotech Ltd FAQs

The current trading price of Q-Line Biotech on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Q-Line Biotech stood at ₹1,588.7 Cr

The latest P/E ratio of Q-Line Biotech as of 31-Dec-1969 is 27.90.

The latest P/B ratio of Q-Line Biotech as of 31-Dec-1969 is 6.24.

The 52-week high of Q-Line Biotech is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Q-Line Biotech is ₹341 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Q-Line Biotech Ltd is a below average quality company.

The key valuation ratios of Q-Line Biotech Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Q-Line Biotech Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Q-Line Biotech Ltd

Q-Line Biotech was originally incorporated as ‘POCT Services Private Limited’ on November 10, 2010 as a Private limited company. Subsequently, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of the company was changed to ‘Q-Line Biotech Private Limited’. Further, pursuant to a special resolution passed by the shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, the company was converted from a private limited company to public limited company and consequently the name of the company was changed to ‘Q-Line Biotech Limited’.

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and In Vitro Diagnostic (IVD) products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The core segments of operations of the company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

Its key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics, Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc. It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. The company works on a B2B model and supplying most of its products to its customers which includes distributors, diagnostic service providers and hospitals.

Business area of the company 

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs.

Products and services of the company

  • Reagent
  • Instrument
  • Consumable/Spare
  • Service

Awards, accreditations and recognition 

  • 2022-23: Received the Certificate of Excellence from Boule for outstanding dedication and service to Boule products.
  • 2023-24: Received an Appreciation Award at JAI-CON 2023 during the 1st State Level Scientific Conference organized by JAI MLAP Punjab.
  • 2023-24: Received the Outstanding Distributor Award 2023 from Shenzhen Lifotronic Technology Co., Ltd. for their professionalism and valuable contribution.
  • 2023-24: In-house R&D recognized by Government of India, Ministry of Science and Technology, Department of Scientific and Industrial Research (DSIR).
  • 2024-25: Awarded with Certificate of Appreciation for participation in Pharmatech & Health East Africa and Medical & Lab East Africa held in Dar Es Salaam, Tanzania.
  • 2024-25: Received the Golden Star Icon Award 2024 for pioneering work in In-Vitro Diagnostics & Associated Equipment.
  • 2024-25: Awarded ‘Most Promising Company in IVD for Make in India initiative’ at the 15th MT India Healthcare Awards 2025 by Medgate Today Magazine.

History and milestones

  • 2010-11: Incorporation of the company as a Private Limited Company in the name and style of ‘POCT Services Private Limited’ founded by Saurabh Garg, Amita Garg and Pushplata Garg.
  • 2014-15: First Branch office at Delhi 20-A Basement, Najafgarh Road, Shivaji Marg, West Delhi, New Delhi - 110015.
  • 2016-17: Established the first manufacturing facility at Plot No. 3, Pocket - H, Sector - 5, Bawana Industrial Complex, Bawana, Delhi – 110039, India.
  • 2018-19: Incorporated an associate company in the name of ‘POCT Science House Private Limited’.
  • 2020-21: Introduced Viral Transport Medium (VTM), Nucleic Acid Extraction Kit and Covid-19 RT-PCR Kit.
  • 2020-21: Expanded ELISA product range with HIV, HCV, and HBsAg kits.
  • 2021-22: Change of the name of the company from ‘POCT Services Private Limited’ to ‘Q-Line Biotech Private Limited’.
  • 2022-23: Expansion of office at Naraina Industrial Area, New Delhi.
  • 2023-24: Incorporated a subsidiary company in the name of ‘Q-Line Nutraceuticals Private Limited’.
  • 2023-24: Incorporated a subsidiary company in the name of ‘IQ-Line Private Limited’.
  • 2023-24: Incorporated an associate company in the name of ‘Q-Line Iris Private Limited’.
  • 2023-24: Established the manufacturing facility at Plot No. 276, Behtwa, Amausi, Station Road, Sarojni Nagar, Lucknow, Lucknow - 226009, Uttar Pradesh.
  • 2023-24: Established the manufacturing facility at Plot No. 3105, Gindan Khera, Amausi Station Road, Nadarganj, Lucknow226008, Uttar Pradesh.
  • 2023-24: Transferred its entire shareholding in ‘IQ-Line Private Limited’ which resulted in it no longer being a subsidiary company.
  • 2024-25: Established the manufacturing facility in 298 and 281, Adjacent Transport Nagar Metro station, Transport Nagar, Lucknow - 226023, Uttar Pradesh.
  • 2024-25: Conversion of the Private Limited Company into a Public Limited Company as per the provisions of the Companies Act, 2013.
  • 2024-25: Acquired shares in ‘Q-line Innovations Private Limited’, making it a subsidiary company.
  • 2024-25: Transferred its entire shareholding in ‘Q-Line Nutraceuticals Private Limited’ which resulted in it no longer being a subsidiary company.
  • 2024-25: Transferred its majority shareholding in ‘POCT Science House Private Limited’ which resulted in it no longer being an associate company.

You have 47 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now